Regulation of the Wnt/β-Catenin Signaling Pathway by Non-Coding RNAs in Esophageal Squamous Cell Carcinoma: Mechanisms, Translational Relevance, and Therapeutic Implications.

IF 4.6 4区 医学 Q3 ONCOLOGY
Oncology Research Pub Date : 2026-08-13 eCollection Date: 2026-01-01 DOI:10.32604/or.2026.081222
Chao Han, Ming Hou, Ruifeng Yang, Xiaoping Wei, Cheng Wang
{"title":"Regulation of the Wnt/β-Catenin Signaling Pathway by Non-Coding RNAs in Esophageal Squamous Cell Carcinoma: Mechanisms, Translational Relevance, and Therapeutic Implications.","authors":"Chao Han, Ming Hou, Ruifeng Yang, Xiaoping Wei, Cheng Wang","doi":"10.32604/or.2026.081222","DOIUrl":null,"url":null,"abstract":"<p><p>Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy characterized by a poor long-term prognosis. Aberrant activation of the canonical Wnt/β-catenin pathway serves as a central oncogenic driver in ESCC, with large-scale genomic analyses revealing that most patients harbor alterations in pathway-associated genes. This signaling axis orchestrates a wide array of malignant phenotypes, including tumor proliferation, invasion, epithelial-mesenchymal transition (EMT), cancer stemness, and therapeutic resistance. Therefore, this review aims to provide a comprehensive synthesis of the multifaceted crosstalk between various ncRNA classes and the Wnt/β-catenin axis, highlighting their roles in ESCC progression and their potential as mechanism-based clinical tools. Emerging evidence identifies non-coding RNAs (ncRNAs)-including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs)-as key regulators of this pathway in ESCC. In this article, we systematically summarize the molecular mechanisms by which 36 unique ncRNA species (20 miRNAs, 10 lncRNAs, and 6 circRNAs) modulate Wnt signaling. Oncogenic ncRNAs promote malignant progression by suppressing negative regulators within complex competing endogenous RNA (ceRNA) networks, whereas tumor-suppressive ncRNAs inhibit pathway activation by targeting Wnt ligands, receptors, or downstream effectors. Furthermore, we discuss the translational relevance of ncRNA-based biomarkers for risk stratification and prognosis in clinical cohorts. Finally, we evaluate pharmacological strategies for ncRNA-based therapeutics while highlighting critical challenges related to delivery efficiency, specificity, molecular stability, off-target effects, tumor heterogeneity, and clinical validation. Ultimately, a clearer understanding of the ncRNA-Wnt regulatory network is essential for developing personalized, mechanism-based diagnostic and therapeutic strategies.</p>","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"34 9","pages":"8"},"PeriodicalIF":4.6000,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494495/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32604/or.2026.081222","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy characterized by a poor long-term prognosis. Aberrant activation of the canonical Wnt/β-catenin pathway serves as a central oncogenic driver in ESCC, with large-scale genomic analyses revealing that most patients harbor alterations in pathway-associated genes. This signaling axis orchestrates a wide array of malignant phenotypes, including tumor proliferation, invasion, epithelial-mesenchymal transition (EMT), cancer stemness, and therapeutic resistance. Therefore, this review aims to provide a comprehensive synthesis of the multifaceted crosstalk between various ncRNA classes and the Wnt/β-catenin axis, highlighting their roles in ESCC progression and their potential as mechanism-based clinical tools. Emerging evidence identifies non-coding RNAs (ncRNAs)-including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs)-as key regulators of this pathway in ESCC. In this article, we systematically summarize the molecular mechanisms by which 36 unique ncRNA species (20 miRNAs, 10 lncRNAs, and 6 circRNAs) modulate Wnt signaling. Oncogenic ncRNAs promote malignant progression by suppressing negative regulators within complex competing endogenous RNA (ceRNA) networks, whereas tumor-suppressive ncRNAs inhibit pathway activation by targeting Wnt ligands, receptors, or downstream effectors. Furthermore, we discuss the translational relevance of ncRNA-based biomarkers for risk stratification and prognosis in clinical cohorts. Finally, we evaluate pharmacological strategies for ncRNA-based therapeutics while highlighting critical challenges related to delivery efficiency, specificity, molecular stability, off-target effects, tumor heterogeneity, and clinical validation. Ultimately, a clearer understanding of the ncRNA-Wnt regulatory network is essential for developing personalized, mechanism-based diagnostic and therapeutic strategies.

非编码rna在食管鳞状细胞癌中调控Wnt/β-Catenin信号通路:机制、翻译相关性和治疗意义
食管鳞状细胞癌(ESCC)是一种高度侵袭性的恶性肿瘤,其特点是长期预后差。典型Wnt/β-catenin通路的异常激活是ESCC的中心致癌驱动因素,大规模基因组分析显示大多数患者存在通路相关基因的改变。这个信号轴协调了一系列的恶性表型,包括肿瘤增殖、侵袭、上皮-间质转化(EMT)、癌症干性和治疗耐药性。因此,本综述旨在全面综合各种ncRNA类别和Wnt/β-catenin轴之间的多方面串扰,强调它们在ESCC进展中的作用及其作为基于机制的临床工具的潜力。新出现的证据表明,非编码rna (ncRNAs)——包括微rna (miRNAs)、长链非编码rna (lncRNAs)和环状rna (circRNAs)——是ESCC中这一途径的关键调控因子。在本文中,我们系统地总结了36种独特的ncRNA物种(20种mirna, 10种lncrna和6种circrna)调节Wnt信号的分子机制。致癌ncRNAs通过抑制复杂竞争内源性RNA (ceRNA)网络中的负调节因子来促进恶性进展,而肿瘤抑制性ncRNAs通过靶向Wnt配体、受体或下游效应物来抑制通路激活。此外,我们讨论了临床队列中基于ncrna的生物标志物在风险分层和预后方面的翻译相关性。最后,我们评估了基于ncrna的治疗方法的药理学策略,同时强调了与递送效率、特异性、分子稳定性、脱靶效应、肿瘤异质性和临床验证相关的关键挑战。最终,更清晰地了解ncRNA-Wnt调控网络对于制定个性化、基于机制的诊断和治疗策略至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Oncology Research
Oncology Research 医学-肿瘤学
CiteScore
4.40
自引率
0.00%
发文量
56
审稿时长
3 months
期刊介绍: Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书